-
Global Chronic Myeloid Leukemia Prevalent Cases Forecast, 2017-2027
DRG Epidemiology presents its first ever global epidemiology forecast for chronic myeloid leukemia (CML) out to 2027. This is made available in the form of a free, downloadable, e-book. Download now...
-
DRG Epidemiology’s Global Leukemia Forecast, 2017-2027
This live session took place on Wednesday, August 2nd, 2017. Dr. Atul Sharma BDS., MPH will present DRG’s epidemiological forecast of all those living with Leukemias worldwide in 2017 and 2027. The...
-
Global Depression Prevalent Cases Forecast, 2017-2027
DRG Epidemiology presents its first ever global epidemiology forecast for depression out to 2027. This is made available in the form of a free, downloadable, e-book. Download now to find out:...
-
Global Acute Lymphoblastic Leukemia Prevalent Cases Forecast, 2017-2027
DRG Epidemiology presents its first ever global epidemiology forecast for acute lymphoblastic leukemia (ALL) out to 2027. This is made available in the form of a free, downloadable, e-book....
-
Global Acute Myeloid Leukemia Prevalent Cases Forecast, 2017-2027
DRG Epidemiology presents its first ever global epidemiology forecast for acute myeloid leukemia (AML) out to 2027. This is made available in the form of a free, downloadable, e-book. Download...
-
Global Alzheimer's Disease Prevalent Cases Forecast, 2017-2027
DRG Epidemiology presents its first ever global epidemiology forecast for Alzheimer’s disease out to 2027. This is made available in the form of a free, downloadable, e-book. Download now to...
-
Trends in Biosimilars Market
Despite biosimilars being available for over ten years in some markets, the biosimilars market continues to evolve. Development of biosimilars is a truly global endeavour, helped by the spread of...
-
The Treatment Landscape in Acute and Chronic Heart Failure
This live session took place on Wednesday, July 19th, 2017. This webinar will discuss the factors that influence cardiologists to select treatments, and the unmet need that remains for the treatment...
-
Will Bioresorbable Vascular Stents Overtake Drug-Eluting Stents As The Gold Standard In CAD Treatment?
Thank you for your interest in Will Bioresorbable Vascular Stents Overtake Drug-Eluting Stents As The Gold Standard In CAD Treatment? Please fill out the form below to access your whitepaper.
-
The Rocky Road For Value-Based Orthopedic Care In The U.S.
Healthcare and legislative leaders in the U.S. have made countless efforts to move away from a supply-driven healthcare system. This is attributable, in part, to an endless number of fraud cases,...
A global consultancy and training agency providing market leading product & portfolio strategy, health economic outcomes research & evidence generation, value communication and training services across the life science industry.
We partner with both the biopharmaceutical and medical technology industry to support commercialization & patient access across a variety of functions including: R&D, commercial strategy, HEOR, market access, new product planning, marketing, data insights & analytics, business development and channel & segment customer engagement.
